RP Bio Inc.
Financials
Valuation Metrics
RP Bio Inc.'s Market Cap is ₩512B. At end of 2025 it was ₩641B. Ranked #1765 of 2,421 in KR market (top 73%), #1076 of 1,640 on KOSDAQ (top 66%), #189 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 82%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 51.22B KRW | KR#1,765/2,421 Sec#189/231 |
| Revenue | 141.42B KRW | KR#1,220/2,421 Sec#75/231 |
| Net Income | 6.73B KRW | KR#1,099/2,421 Sec#69/231 |
| Total Assets | 170.50B KRW | KR#1,415/2,421 Sec#106/231 |
| Net Assets | 116.75B KRW | KR#1,309/2,421 Sec#104/231 |
| Employees | 493 | KR#501/2,421 Sec#42/231 |
| Value | ||
| P/E | 7.62x | KR#629/2,421 Sec#29/231 |
| P/B | 0.44x | KR#657/2,421 Sec#22/231 |
| PEG | 0.06x | KR#345/2,421 Sec#18/231 |
| P/S | 0.36x | KR#704/2,421 Sec#20/231 |
| EV/EBITDA | 7.62x | KR#441/2,421 Sec#18/231 |
| FCF Yield | 14.21% | KR#460/2,421 Sec#12/231 |
| Profitability | ||
| ROE | 5.76% | KR#1,004/2,421 Sec#69/231 |
| ROA | 3.94% | KR#884/2,421 Sec#71/231 |
| Op. Margin | 5.28% | KR#929/2,421 Sec#70/231 |
| Revenue Growth | 9.55% | KR#929/2,421 Sec#91/231 |
| Earnings Growth | 121.62% | KR#352/2,421 Sec#23/231 |
| Financial Health | ||
| Debt Ratio | 46.04% | KR#904/2,421 Sec#103/231 |
| Total Debt | 16.00B KRW | KR#1,469/2,421 Sec#123/231 |
| FCF | 7.28B KRW | KR#805/2,421 Sec#50/231 |
| Cash | 10.28B KRW | KR#1,675/2,421 Sec#142/231 |
| Current Ratio | 1.42x | KR#1,270/2,421 Sec#135/231 |
| Net Debt/EBITDA | 0.77x | KR#709/2,421 Sec#47/231 |
| Dividend | ||
| Div. Yield | 0.84% | KR#1,165/2,421 Sec#70/231 |
| Performance | ||
| 1Y Return | -15.81% | KR#1,139/2,421 Sec#75/231 |
| 1M Return | -2.80% | KR#1,565/2,421 Sec#125/231 |
| From 52W High | -35.27% | KR#720/2,421 Sec#47/231 |
| 1Y MDD | -36.83% | KR#461/2,421 Sec#35/231 |
| Trading | ||
| Volume | 27,254 shares | KR#1,433/2,421 Sec#142/231 |
| Trading Value | 160.0M KRW | KR#1,356/2,421 Sec#139/231 |
| Foreign Own. | 2.09% | KR#1,596/2,421 Sec#152/231 |
| Per Share | ||
| EPS | 776 KRW | KR#819/2,421 Sec#59/231 |
| BPS | 13,472 KRW | KR#770/2,421 Sec#52/231 |
Company Info
RP Bio, established in 2016 through a spin-off and listed on KOSDAQ in 2022, is the sole domestic company inheriting Dr. RP Scherer's soft capsule manufacturing technology since 1983. The company manufactures and supplies various pharmaceuticals and health functional foods, including soft capsules, holding over 60% of the domestic soft capsule market share. RP Bio maintains long-term collaborations with major pharmaceutical companies, possesses 28 patents, and pursues global market expansion strategies based on its quality competitiveness.